Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs
The Danish company seeks to convince investors it can compete in an increasingly crowded field it helped pioneer.
The Danish company seeks to convince investors it can compete in an increasingly crowded field it helped pioneer. This story matters for Finance & Markets readers tracking fund. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. FundNews curates and briefs the finance & markets stories that matter. Our editorial policy →